NCT04220034View on ClinicalTrials.gov

Autoantibodies Prevalence During Checkpoint Inhibitor Treatment

Active, not recruitingOBSERVATIONAL

Enrollment

150

Participants

Timeline

Start Date

January 15, 2020

Primary Completion Date

October 15, 2024

Study Completion Date

December 15, 2024

Conditions

Autoimmune Adverse Effects of Anti-neoplasic Drug

Interventions

BIOLOGICAL

Blood sample

Blood sample will be collected to determine development or increase level frequencies of different types of autoantibodies in patients receiving ICI for the first time

Trial Locations (1)

51092

Chu Reims, Reims

All Listed Sponsors

lead

CHU de Reims

OTHER